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Introduction
• Definition- Acute inflammatory lung injury 
associated with increased pulmonary vascular 
permeability, increased lung weight, and loss 
of aerated lung tissue (Bellani et al., 2016).
• Initially defined in 1967 in the Observational 
Lung Study in The Lancet (Pham & Rubenfeld, 
2017).
• 10-15% of patients admitted to ICUs are 
diagnosed with ARDS (Siegel, 2020).
• Incidence of ARDS in the United States are 
64.2 to 78.9 cases per 100,000 person years 
(Diamond et al., 2020).
• Incidence increases with patient age and 
increased severity (Diamond et al., 2020).
• Mortality increases with severity 27% with 
mild, 32% with moderate, and 45% with 
severed, overall ARDS has a mortality of 43% 
(Diamond et al., 2020).
Signs and Symptoms
• Berlin Definition: Respiratory failure within 
one week of a known insult, not entirely by 
cardiac function or volume overload, with 
bilateral opacities seen on chest radiography 
or chest CT scan (Matthay et al., 2019).
• Severity is defined by the PaO2/FiO2 ratio. 
Mild ARDS P/F between 201-300 mmHg, 
Moderate ARDS P/F between 101-200 mmHg, 
Severe ARDS P/F ratio <101 mmHg (Matthay 
et al., 2019).
• Dyspnea, hypoxemia, rapid onset and 
worsening shortness of breath.
• Central and peripheral cyanosis, tachycardia, 
altered mental status, decreased oxygen 
saturations, rales on lung auscultation (Mayo 
Clinic, 2018).
• Risk Factors include advanced age, female 
gender, smoking, alcohol use, aortic vascular 
surgery, cardiovascular surgery, and 
traumatic brain injury (Diamond et al., 2020). 
• Genetic component to ARDS (Sweeney & 
McAuley, 2016). 
Chest X-ray of ARDS patient (Diamond et al., 2020).
Underlying Pathophysiology 
Three phases of ARDS exudate, proliferation, fibrotic.  
Initial lung injury can be caused by pneumonia, non-
pulmonary sepsis, aspiration, or major trauma (Matthay 
et al., 2019).
Exudate (Inflammatory) Phase 
Occurs within the first 72 hours after initial lung 
injury. Initial injury causes diffuse alveolar damage. In 
response to the damage proinflammatory cytokines (IL-
8, TNF-α) are released.  Cytokines bring neutrophils to 
the lungs.  Neutrophils activate and release toxic 
mediators  (reactive oxygen species and nitric oxide). 
Toxic mediators damage endothelium and alveolar 
epithelium (McCance & Huether, 2018). Capillary 
endothelium damage causes proteins to escape the 
vascular space.  The oncotic gradient is lost allowing fluid 
to leak into the interstitium, backing up the lymphatic 
system. Increased interstitial fluid along with damage to 
the alveolar epithelium causes the air space to fill with 
fluid and cellular debris.  Platelet and compliment system 
are activated causing microvascular microthrombus 
formations damaging the lung epithelium. Pulmonary 
vasoconstriction occurs causes pulmonary hypertension 
(Siegel, 2020). Impaired type 2 alveolar cells production 
related to bronchioles fluid overload and collapse. Type 2 
alveolar cells unable to produce surfactant increasing 
alveolar collapse.  Overall decreased lung compliance, 
increased work of breathing, decreased ventilation of 
alveoli, and hypercapnia (McCance & Huether, 2018).
Proliferative Phase
Occurs around one to three weeks 
after the initial injury. Start of healing 
of the lungs. First the pulmonary 
edema begins to resolve. Fibroblasts, 
myofibroblasts and type 2 
pneumocytes start to proliferate. 
With the proliferation of  type 2 
pneumocytes surfactant production is 
restored.  Type 1 pneumocytes 
proliferate also, regenerating the cell 
epithelium. (McCance & Huether, 
2018). This phase overlaps with the 
final phase. 
Fibrotic Phase
Occurs two to three week after the 
initial injury. During this time cells 
remodel and fibrosis occurs Fibrosis 
causes damage to alveoli, respiratory 
bronchioles and the interstitium.  Fibrosis 
causes a decreasing in the residual 
capacity of the lungs, creating severe 
right to left shunting and respiratory 
failure. Also can cause increased 
pulmonary hypertension.  This phase 
accounts for long term damage to the 
lungs (McCance & Huether, 2018).
Alveolar damage causes by ARDS (Matthay et al., 2019)
The Significance of 
Pathophysiology 
The chemical 
mediator released during 
ARDS causes systemic 
effects triggering SIRS 
and can eventually lead 
to multi-system organ 
failure and death 
(McCance & Huether, 
2018).  Most patients do 
not die from ARDS but 
from the complications 
caused to other systems. 
Short term complications 
include blood clots, 
collapsed lungs, 
infections and scarring. 
Long term complication 
include breathing 
problem , depression, 
memory and cognitive 
problems, and muscle 
weakness (Mayo Clinic, 
2018). 
Implication for Nursing Care
Pathophysiology and 
management of ARDS 
(Sweeney & McAuley, 2016) 
There	is	no	cure	for	ARDS,	but	treatment	goals	are	supportive	care	to	reduce	
shunting,	increase oxygen delivery, decrease oxygen consumption, and avoid further injury 
(Diamond et al., 2020). 
Oxygenation
In mild ARDS delayed intubation decreases mortality. In mild ARDS bipap/cpap or 
heated high flow oxygen are the preferred oxygenation method (Matthay et al., 2019).
Intubated ARDS patients require smaller tidal volumes because of the non-uniformity of 
aerations and decreasing overdistention.  Determining the correct tidal volume is patient 
specific.  One method uses the driving pressure (plateau pressure – PEEP) to determine tidal 
volume (Matthay et al., 2019). The ARMA study found using 6ml per kg of tidal volume with 
a plateau pressure less than 30, decreased mortality by 8.8% and lead to more vent free 
days (Sweeney & McAuley, 2016). 
Additional treatment includes increasing the positive end-expiratory pressure (PEEP). 
Researchers have found by using higher PEEP patients maintain better oxygenation and 
alveolar recruitment (Matthay et al., 2019). A meta-analysis of PEEP found increased levels 
of PEEP lowered hospital mortality and had less requirements of mechanical ventilation by 
day 28 (Sweeney & McAuley, 2016). 
In ARDS patients ARDSnet protocol is used to wean patients from the ventilator by 
correlating the FIO2 and PEEP requirements (Diamond et al., 2020).
Finally ARDS requires different ventilation modes to better oxygenate the lungs. ARDS 
patients may require changing the inspiratory-to –expiratory ratio or even creating an 
inverse ratio.  In adults the preferred vent mode is Airway Pressure Release Ventilation 
(APRV). APRV provides increased oxygenation but has no benefit on mortality (Diamond et 
al., 2020).
Pronation
Another treatment of ARDS patients is placing them in a prone position. The prone 
position provides a more uniform distribution of lung stress and strain, improving 
ventilation and lung/chest wall mechanisms. The PROSEVA study found pronation 
decreased 28- and 90-day mortality, increased ventilator free days, and decreased time to 
extubation (Koulouras et al., 2016). Pronation benefits about 50-70% of patients if started 
within the first week and kept prone for at least eight hours a day for consecutive days. 
(Diamond et al., 2020).
Fluid Management
Conservative fluid management, with the use of 
diuretics, after initial resuscitation of shock was 
found to improve outcomes (Matthay et al., 2019).
Medications
Neuromuscular blockade agents (NMBA) are 
used to increase ventilator compliance.  They are 
current best practice and have been shown to 
improve 90-day survival and increase time off the 
ventilator (Diamond et al., 2020). A recent study by 
Petal Clinical Trials Networks (2019) found no 
mortality difference comparing the use of NMBA to 
patients using light sedation.  The new research 
could change current practice, but current practice is 
supportive of NMBA. 
Inhaled pulmonary vasodilators have selective 
vasodilation of the pulmonary circulation providing 
increased ventilation-perfusion matching and 
increased oxygenation (Matthay et al., 2019).
Methyl-prednisone is used in the treatment of 
ARDS but does not show any benefits in comparative 
studies.  Steroids have been found to help resolve 
shock and respiratory failure but increase 
neuromuscular weakness. Patients started on 
steroids later in the course of the illness had 
increased mortality rates (Matthay et al., 2019)
No other medications have proven beneficial in 
the treatment and management of ARDS (Sweeney 
& McAuley, 2016). 
ECMO
Veno-venous extracorporeal membrane 
oxygenation (ECMO) has proven beneficial with 
severe ARDS patients started within the first week 
with no organ failure (Matthay et al., 2019). 
Extracorporeal carbon dioxide removal removes CO2 
from the venous blood and allows the use of low 
tidal volumes without the resulting acidosis 
(Matthay et al., 2019). Unfortunately ECMO is a 
specialized procedure and few hospitals have the 
resources or technology to provide.
Conclusion 
ARDS is the result of an initial lung injury causing 
respiratory failure and can lead to multi-system 
organ failure.  Research shows that ARDS is 
underrecognized causing delays in treatment 
initiation resulting in increased patient mortality. 
Early recognition and treatment of ARDS provides 
better patient outcomes (Bellani et al., 2016).
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